Adenovirus vectors
AssigneeUniversity of Michigan
InventorsJeffrey S. Chamberlain, Rajendra Kumar-Singh
Life of this patent
Estimating the term…
Abstract
The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
Claims11
A recombinant plasmid, comprising in operable combination:
- a) a plasmid backbone, comprising an origin of replication, an antibiotic resistance gene and a eukaryotic promoter element;
- b) the left and right inverted terminal repeats (ITRs) of adenovirus, said ITRs each having a 5' and a 3' end and arranged in a tail to tail orientation on said plasmid backbone;
- c) the adenovirus packaging sequence, said packaging sequence having a 5' and a 3' end and linked to one of said ITRs;
- and
- d) a gene of interest operably linked to said promoter element.
Dependencies are inferred from the claim text.